Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Actelion acquires Axovan

Executive Summary

Actelion Ltd. (develops drugs that act on the endothelium) has agreed to acquire the 91% of Axovan AG (G protein-coupled receptor drug targets) it did not already own. Axovan is valued at CHF60mm ($45.2mm) and at the time of the agreement had a cash position of $11mm.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Earnout
    • Intra-Biotech Deal
    • Partial Acquisition

Related Companies